Adjuvant therapy for resected pancreatic cancer
نویسندگان
چکیده
منابع مشابه
Adjuvant therapy for pancreatic cancer.
Survival for patients with pancreas cancer is correlated to stage. Only 20% of patients present with localized disease amenable to potentially curative resection but, despite resection, the 5-year survival rate for early stage patients remains less than 25%. Current accepted standard of care is adjuvant gemcitabine following curative resection but there have been no conclusions regarding the ro...
متن کاملAdjuvant therapy in pancreatic cancer.
Pancreatic cancer is one of the major causes of cancer death in Europe with a 5-year survival rate of less than 5%. Although surgery cannot guarantee a cure, the 5-year survival does improve to around 10% following resection and increases to 20-30% with adjuvant chemotherapy. The European Study Group for Pancreatic Cancer (ESPAC) 1 trial was the first adequately powered, randomized study to ass...
متن کاملAdjuvant therapy of pancreatic cancer.
Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the...
متن کاملAdjuvant therapy for pancreatic cancer: current status.
Only 5% to 15% of patients with pancreatic adenocarcinoma are candidates for a potentially curative resection. Evidence that postoperative adjuvant therapy improves outcome has been limited to a single randomized trial of a well tolerated split-course, 5-Fluorouracil (5-FU) based, chemoradiation regimen. More aggressive regimens have since been developed and are associated with, at best, a mode...
متن کاملInterferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer.
AIM Interferons (IFNs) are known to have antiproliferative and immunoregulatory activities that are modulated through specific cell surface ligands, known as IFN-alpha, -beta, and -gamma receptors. The presence of these receptors and their impact on response to adjuvant therapy in patients with pancreatic cancer has not been determined. PATIENTS AND METHODS Slides were prepared from 46 patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2017
ISSN: 1465-1858
DOI: 10.1002/14651858.cd011514.pub2